Johnson & Johnson flagged as IBD Stock Of The Day as it heads into its June-quarter earnings
IBD named Johnson & Johnson its Stock Of The Day for Monday, pointing to a bullish setup into the company’s next earnings release.
Johnson & Johnson company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
IBD named Johnson & Johnson its Stock Of The Day for Monday, pointing to a bullish setup into the company’s next earnings release.
THE APEX TIMES
Johnson & Johnson said it has launched a Dual Energy THERMOCOOL SMARTTOUCH SF ablation catheter in Europe, indicating continued investment in cardiology device offerings as it expands access to heart-rhythm treatment tools.
In a June 17 comment covered by Yahoo Finance, Johnson & Johnson’s chief executive said the company does not plan to move into the obesity drug market, while reinforcing a strategy centered on oncology and neuroscience.
A regulatory update in Europe involving Johnson & Johnson’s Tecvayli in combination with Darzalex SC adds to the company’s cancer pipeline progress, while the latest market chatter around a talc verdict focuses on easing one legal overhang.
A recent market analysis argues Bristol Myers Squibb’s shares are priced well below peers while Johnson & Johnson’s business mix supports stronger profitability, but the comparison also raises questions about what each company is paying for growth and risk.
A new Yahoo Finance item highlights Johnson & Johnson as a “trending stock” among Zacks.com users, pointing readers to the questions investors typically weigh before making decisions.
A steep one-year run has pushed Johnson & Johnson’s stock near new highs, raising the question of whether the company’s underlying fundamentals still offer room for returns at current levels.
The move follows a higher-than-average trading session and growing attention to whether analysts are revising profit forecasts upward for Johnson & Johnson.
A Los Angeles jury ruled in favor of Johnson & Johnson in a lawsuit alleging talc products caused cancer in three women, according to a Reuters report carried by Yahoo Finance.